Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bronwyn Stuckey

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
The Australian & New Zealand Journal of Obstetrics & Gynaecology|July 19, 2012
Waiting for an elevated FSH--too late a marker of reduced ovarian reserve?Kalani Mudhitha Kahapola Arachchige, Robert Wardrop, Ee Mun Lim, et al.
Menopause (New York, N.Y.)|August 25, 2023
A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal womenAndrea Thurman, M Louise Hull, Bronwyn Stuckey, et al.
Menopause (New York, N.Y.)|June 20, 2023
A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal womenAndrea Thurman, M Louise Hull, Bronwyn Stuckey, et al.
The Journal of Sexual Medicine|September 1, 2006
Vardenafil improved erectile function in a "real-life" broad population study of men with moderate to severe erectile dysfunction in Australia and New ZealandChris McMahon, Douglas Lording, Bronwyn Stuckey, et al.
The Journal of Sexual Medicine|November 17, 2009
Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data studyKew-Kim Chew, Judith Finn, Bronwyn Stuckey, et al.
Plos One|September 2, 2016
Long-Term Effects of a Randomised Controlled Trial Comparing High Protein or High Carbohydrate Weight Loss Diets on Testosterone, SHBG, Erectile and Urinary Function in Overweight and Obese MenLisa J Moran, Grant D Brinkworth, Sean Martin, et al.
The Journal of Sexual Medicine|March 21, 2012
A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunctionEusebio Rubio-Aurioles, Hartmut Porst, Edward D Kim, et al.
Trials|June 21, 2019
Recruitment of men to a multi-centre diabetes prevention trial: an evaluation of traditional and online promotional strategiesKaren Bracken, Wendy Hague, Anthony Keech, et al.
Diabetes, Obesity & Metabolism|December 7, 2018
Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trialGary Wittert, Evan Atlantis, Carolyn Allan, et al.
Clinical Trials (London, England)|October 5, 2019
A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trialKaren Bracken, Anthony Keech, Wendy Hague, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
The Australian & New Zealand Journal of Obstetrics & Gynaecology|July 19, 2012
Waiting for an elevated FSH--too late a marker of reduced ovarian reserve?Kalani Mudhitha Kahapola Arachchige, Robert Wardrop, Ee Mun Lim, et al.
Menopause (New York, N.Y.)|August 25, 2023
A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal womenAndrea Thurman, M Louise Hull, Bronwyn Stuckey, et al.
Menopause (New York, N.Y.)|June 20, 2023
A phase 1/2, open-label, parallel group study to evaluate the safety and pharmacokinetics of DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal rings) over 12 weeks in healthy postmenopausal womenAndrea Thurman, M Louise Hull, Bronwyn Stuckey, et al.
The Journal of Sexual Medicine|September 1, 2006
Vardenafil improved erectile function in a "real-life" broad population study of men with moderate to severe erectile dysfunction in Australia and New ZealandChris McMahon, Douglas Lording, Bronwyn Stuckey, et al.
The Journal of Sexual Medicine|November 17, 2009
Erectile dysfunction as a predictor for subsequent atherosclerotic cardiovascular events: findings from a linked-data studyKew-Kim Chew, Judith Finn, Bronwyn Stuckey, et al.
Plos One|September 2, 2016
Long-Term Effects of a Randomised Controlled Trial Comparing High Protein or High Carbohydrate Weight Loss Diets on Testosterone, SHBG, Erectile and Urinary Function in Overweight and Obese MenLisa J Moran, Grant D Brinkworth, Sean Martin, et al.
The Journal of Sexual Medicine|March 21, 2012
A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunctionEusebio Rubio-Aurioles, Hartmut Porst, Edward D Kim, et al.
Trials|June 21, 2019
Recruitment of men to a multi-centre diabetes prevention trial: an evaluation of traditional and online promotional strategiesKaren Bracken, Wendy Hague, Anthony Keech, et al.
Diabetes, Obesity & Metabolism|December 7, 2018
Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trialGary Wittert, Evan Atlantis, Carolyn Allan, et al.
Clinical Trials (London, England)|October 5, 2019
A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trialKaren Bracken, Anthony Keech, Wendy Hague, et al.
Pageof 3